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Abstract
Introduction
Atrial fibrillation is the most prevalent cardiac arrhythmia 
worldwide, which is diagnosed in many patients each day and 
increases as a patient ages. Anticoagulation therapy is a major part 
of treating the patient and there are many anticoagulants to choose 
from. The options include aspirin, vitamin K antagonist like 
warfarin, factor Xa inhibitors like rivaroxaban and apixaban, direct 
thrombin inhibitors like dabigatran, and antiplatelet agent such as 
clopidogrel. All of the different types of anticoagulation options 
can make treatment quite difficult given the diversity. The purpose 
of this study is to determine what anticoagulants are most effective 
in preventing clot formation that could lead to a stroke, but have 
the lowest occurrence of adverse effects such as fatal bleeding.  
With atrial fibrillation becoming increasingly more prevalent as a 
person ages and the many options available for anticoagulation, it 
can be difficult to decide which anticoagulant is most appropriate. 
Research Question
Literature Review Applicability to Clinical 
Practice
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Discussion
• Atrial fibrillation is a common disease that people are diagnosed 
with more and more as they age. There are many different 
medications that are prescribed when a diagnosis of atrial 
fibrillation is made. One of the new additions to their 
medication regimen is an anticoagulant. 
• Previously, warfarin had been the anticoagulant of choice and 
most people had been placed on warfarin for ischemic stroke 
prophylaxis. There are many things to consider when choosing 
an anticoagulant. While on warfarin patients need to have blood 
tested regularly to make sure it maintains at recommended 
levels. Warfarin does take more time to get to a therapeutic level 
and can be very difficult to keep patients at this acceptable level. 
There are also many interactions with different drugs and even 
certain foods.  
• The new addition of the novel oral anticoagulant agents is 
appealing to both patients and providers. With this medication, 
the patient does not have to have blood drawn multiple times a 
week to check their therapeutic level. The downside to these 
medications with them being newer, is their cost and they 
should not be used in patients with renal impairment. Many of 
the patients with atrial fibrillation taking anticoagulant therapy 
are elderly and cannot afford the new novel oral anticoagulants. 
The prescriber needs to consider the patient’s current 
medication list, their renal function as well as if the patient will 
be able to afford the medication. 
• Atrial fibrillation increases in occurrence as we age with about 
9% of patients developing it by age 90. When a patient is 
diagnosed with atrial fibrillation, one of the drugs that they are 
prescribed is an anticoagulant. The purpose of this drug is to 
prevent thrombus formation in addition to preventing an 
ischemic stroke. Today, there are many options available for 
anticoagulation therapy. The options include aspirin, vitamin K 
antagonists like warfarin, factor Xa inhibitors like rivaroxaban 
and apixaban, direct thrombin inhibitors like dabigatran, and 
antiplatelet agents such as clopidogrel.  
• A review of the literature was done of peer reviewed journal 
articles using the databases PubMed, Dynamed, CINAHL and 
Clinical Key.  A total of 14 articles were used in this paper with 
the inclusion criteria of being published within the past five 
years, the patients all have atrial fibrillation, over 65 years old, 
and are on some form of anticoagulation therapy. 
• Previously, warfarin has been one of the few anticoagulation 
drugs on the market until the newer novel anticoagulants were 
released. Bell et al. (2016) found that warfarin is still used in 
53.6% of the patients, even though the prevalence has decreased 
by 3.9% between the years of 2011 and 2013. (p <.001) 
• It was found that patients who were diagnosed with atrial 
fibrillation needed some form of anticoagulation as compared to 
no anticoagulation to reduce stroke. Most of the studies 
compared warfarin versus no anticoagulation treatment. There 
were not many studies that looked at the newer novel 
anticoagulants.  It was mentioned that there has been a decrease 
in warfarin use since the newer novel anticoagulants have been 
released. There are considerations that a prescriber needs to be 
conscious of before prescribing a specific anticoagulant.  Some 
of these considerations are renal function, other medication 
usage to avoid drug-drug interactions and age. 
In patient diagnosed with Atrial Fibrillation, is there an 
anticoagulation therapy that is superior to the others for use in the 
elderly?
When a patient is diagnosed with a new disease, there needs to 
be a conversation between the provider and the patient.  With 
the addition of atrial fibrillation as a diagnosis to their list of 
previous diagnoses, the provider and the patient need to sit 
down and discuss the patient’s options. Together they need to 
decide which anticoagulant would be the best for that specific 
patient both for the health of the patient, to make sure it is a 
medication the patient will be willing to adhere to and make sure 
they are able to afford the medication. Patients see many new 
advertisements for the newer novel anticoagulation therapies 
without fully understanding the difference between the different 
types of drugs. It is the job of the provider to explain the 
differences between the anticoagulants, so they can come up 
with a regimen that works best for the patient regarding their age, 
renal function, bleeding and stroke history, and the amount of 
medications they are on. With this communication between 
provider and patient, hopefully there will be an increase in 
compliance of anticoagulant use as well as a decrease in the 
amount of ischemic strokes in patients with atrial fibrillation. 
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Pathophysiology 
The heart contracts due to electrical impulses or action potentials 
that travel from the sinoatrial (SA) node to the atrioventricular (AV) 
node. The action potentials travel from the SA node through the 
myocardium of the atrium and cause a contraction.  In a patient 
with atrial fibrillation, these electrical impulses become 
unorganized and result in multiple stimulations of the 
myocardium, which causes the atrium to contract in an 
uncoordinated fashion. This uncoordinated contraction leads to the 
atrium being unable to fully contract and empty blood from the 
chambers. This can leave blood in the atrium and this blood can 
start to clot, which could then travel to the brain and cause a 
stroke. 
• Ng et al. (2015) did a subgroup analysis of the AVERROES trial 
determines that patients over 85 had less risk of hemorrhagic 
bleeding when on apixaban compared to aspirin. 
• A study done by Yamashita et al. (2016) determined that in the 
elderly over 85, stroke risk increased whether the patient was on 
anticoagulation or not. 
• An analysis looked at the ROCKET AF study done by Hankey et 
al. (2014) evaluated the risk of intracranial hemorrhage 
comparing warfarin versus rivaroxaban. They found that there 
was no major different of intracranial hemorrhage between these 
two medications. 
• Staerk et al. (2016) did a study using the RE-LY, ATRISOTLE, and 
AVERROES trials to study the different anticoagulation therapies. 
They found that the new novel anticoagulants continue to rise in 
use, but warfarin is still superior in patients with renal failure. 
• An analysis done by Piccini et al. (2016) used the ROCKET AF 
study to look at the effects that multiple medications had on the 
use of warfarin or rivaroxaban in patients with atrial fibrillation. 
They found that as the number of multiple medications 
increases, so does the chance of bleeding in patients with atrial 
fibrillation. 
With increases of Atrial Fibrillation as a person ages, studies 
are needed to show if the new oral anticoagulants are superior 
to warfarin. 
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